News | November 07, 2025
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Subscribe To Our Newsletter & Stay Updated
